Tomosynthesis Mammographic Imaging Screening Trial (TMIST) principal investigator Etta Pisano, MD, will lead an informational session at RSNA for radiology department or practice leaders interested in taking part in this landmark study. The TMIST New Investigator meeting will take place November 27 at 2 p.m. Central Time in Room w193-A at McCormick Place in Chicago.
TMIST is enrolling 165,000 healthy women, ages 45 to 74, who are already planning to get routine mammograms. It is the first large randomized, controlled trial (RCT) that seeks to identify groups of women in which tomosynthesis (3D mammography) may be more effective than conventional (2D) mammography at reducing a woman’s odds of developing an advanced breast cancer.
TMIST will create the world’s largest curated dataset of breast cancer screening clinical data, images and bio-specimens to inform future screening policy. Patients will be asked to voluntarily submit blood samples and swabs of buccal cells from the inside of the mouth. TMIST researchers will analyze study-related biopsy tissue to learn more about the biology of screening-detected cancers.
Previous, smaller prospective studies have shown that breast tomosynthesis reduces the number of call backs and false positive exams, while finding more overall cancers — compared to standard mammography. This previous, well-respected research helped prompt federal funding of TMIST — the largest randomized, controlled breast cancer screening trial in decades.
RCTs are recognized as the gold standard in clinical research. Government and private sector decision makers rarely update clinical and payment policy without considering RCTs as part of any evidence base.
To receive information on becoming a TMIST study site, contact Jessica Howell, TMIST Project Manager, at JHowell@acr.org.
For more TMIST information and a list of participating centers, see:
To find TMIST information on social media: #TMIST4BC